About this trial
The purpose of this study is to determine if prolonged fasting from solids and transitioning to a CLD for 24 hours is protective to decrease RGC in patients on GLP-1 RAs presenting for upper endoscopy, to determine if prolonged fasting is associated with increased thirst, hunger and anxiety, To determine if signs and symptoms of nausea, vomiting, retching, abdominal bloating, and abdominal pain are present on the day of surgery, to see if there is any variability between preoperative gastric ultrasound assessment and volume of gastric contents visualized on upper endoscopy, to determine time of gastric emptying by serial Gastric ultrasonography (GUS) scans every 2 hours in subjects who presented with an initial at-risk scan, to determine the choice of anesthesia used based on preoperative GUS results, to determine if there were any adverse events recorded in this study group, to determine if duration of GLP-1 RA therapy has an association with residual gastric content (RGC). and to determine if dosing of GLP-1 RA has an association with RGC.
Eligibility criteria
Qualifiers
Patients taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) agonists
Undergoing upper endoscopy only - no colonoscopy due to prep
Disqualifiers
Previous gastric resection or bypass
Gastric band in situ
Previous fundoplication
Large hiatal hernia
Trial design
Treatments tested in this trial
- GLP-1 RA users with prolonged fasting instructions
- GLP-1 RA users with standard NPO instructions